tbuckley/cabot-search huggingface dataset:
From the NIH: Experiments in the United States suggest faulty data in reports of Soviets rejoining spinal cords
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Urology
Authors: John M. Palmer
Journal: JAMA (1987)

Recent advances in urology range from developments in basic science to progress in diagnosis and treatment and from disorders in the fetus to those in the elderly. Insights into the physiology of erection, for example, have profoundly influenced our ability to treat the impotent patient. Intracavernous injections of the powerful vascular smooth-muscle relaxant papaverine will induce an erection that may last several hours in patients with adequate penile blood supply. This occurs in most patients with neurogenic disease, but patients with vascular disease will have either delayed erections or none at all. Papaverine alone or with phentolamine mesylate is now being used in many centers to successfully treat patients with neurogenic and moderate vascular disease.<sup>1</sup>Most patients are self-administering the regimen with no difficulty. Over 200 000 patients worldwide have now been treated with electroshock wave lithotripsy (ESWL), which has proved to be safe and effective in fragmenting renal
Experimental Study of Biological Effects of Lead and Aluminum Following Oral Administration
Authors: G. N. Krasovskii, L. Y. Vasukovich, O. G. Chariev
Journal: Environmental Health Perspectives (1979)

A wide spectrum of the biological effects of lead and aluminum ions is noted during short-term and long-term oral administration to laboratory animals.The general toxic and gonadotoxic effects of these metals during a short-term experiment appeared to be identical, and the correlation of these effects was preserved during chronic experiments.Lead (0.03 mg/I.) and aluminum (0.5 mg/I.)concentrations in water may be dangerous to the health of the population, and hygienic standards are recommended for inclusion in the standard for drinking water quality.
Field Surgery in Total War
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical efforts intensify in Desert Storm's fourth week
Authors: P. Gunby
Journal: JAMA (1991)

THE SPECTER of Desert Storm ground combat is intensifying military medical efforts. The surgeons general of the US Air Force, Army, Navy, and the medical officer of the US Marine Corps say they are pleased with the quantity, quality, and mix of skills of physicians and other medical team members in the theater of operations and in follow-up care facilities. But they emphasize that they are continuing to assess the medical situation day by day. Like all physicians involved, these military medical leaders are aware of the 3-km-wide obstacle course of 5-m-high sand-berm barriers, coiled razor-sharp wire, 7-m-deep antitank ditches, barbed wire, mine fields, and dug-in armored vehicles and artillery along the 180-km front that faces coalition ground forces. They and their Desert Storm physicians have spent the time available to them in preparing for how to treat wounds inflicted by the Soviet-made AK-47 weapons (with which the world's fourth-largest
The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno‐occlusive disease after stem cell transplantation
Authors: Kazuteru Ohashi, Juichi Tanabe, Reiko Watanabe, Takeshi Tanaka, Hisashi Sakamaki, Atsuo Maruta, Shinichiro Okamoto, Nobuyuki Aotsuka, Kenji Saito, Miki Nishimura, Hakumei Oh, Michio Matsuzaki, Satoshi Takahashi, Shuji Yonekura
Journal: American Journal of Hematology (2000)

Hepatic veno-occlusive disease (VOD) is a common transplant-related complication of stem cell transplantation. There is no safe and proven therapy for established VOD, and attempts have focused on its prevention. Limited studies have suggested that prophylactic use of ursodeoxycholic acid (UDCA) reduced the incidence of VOD. To confirm the preventive effect of UDCA on VOD, we conducted a prospective, unblinded randomized, multicenter study of UDCA involving 132 patients who underwent stem cell transplantation for a variety of disorders. Sixty-seven patients were assigned to the UDCA-treated group, and 65 patients were assigned to the control group. The clinical characteristics of the two groups were similar with respect to primary diagnosis, age, sex, and baseline organ function. The preparative regimen and GVHD prophylaxis did not differ significantly between the two groups. UDCA was highly effective in preventing VOD, which occurred in only 3.0% in the UDCA-treated group, as opposed to 18.5% in the control group (P = 0.0043). There were no adverse effects attributable to UDCA. The initial promising report of a prophylactic effect of UDCA on VOD after stem cell transplantation was confirmed in this prospective study. Am. J. Hematol. 64:32–38, 2000. © 2000 Wiley-Liss, Inc.
Carcinoma in choledochal cyst
Authors: J. R. Macfarlane
Journal: JAMA (1967)

Choledochal cysts are congenital malformations and can be classified into four types. The type 1 lesion is the usual form; the others are extremely uncommon. The treatment in most cases should be surgical drainage into the gastrointestinal tract, preferably using the jejunum in Roux-en-Y fashion. The presence of a carcinoma within the cyst requires excision of the cyst if technically feasible as this offers the best hope for cure. The role of prolonged exposure of the cyst epithelium to stagnant bile in the etiology of the carcinoma has not yet been settled. Two patients with carcinoma in a choledochal cyst were treated at the New York Hospital—Cornell Medical Center.
New Clothes for the Lady
Authors: J. R. E.
Journal: Annals of Internal Medicine (1961)

Editorials1 July 1961New Clothes for the LadyJ. R. E.J. R. E.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-55-1-165 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen the lady of the house announces a little shopping trip down town "just to look around," we all know the inevitable result—a new hat, a new dress, or even a whole new outfit. Of course the old hats or dresses are not worn out, but, for reasons unfathomable to the male mind, the feminine psyche has an urge that must be met. Itismet, the feminine spirit is lifted, and just as inevitably, masculine approval (feigned or real) is necessary for peace on the domestic scene. The ANNALS, with spirit lifted, has come home in a whole new... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byJ. Russell Elkinton, M.D., M.A.C.P.: A TributeMARSHALL N. FULTON, M.D. 1 July 1961Volume 55, Issue 1Page: 165-166 ePublished: 1 December 2008 Issue Published: 1 July 1961 PDF downloadLoading ...
THE SMEGMA BACILLUS AS A DISTURBING FACTOR IN THE DIAGNOSIS OF GENITOURINARY TUBERCULOSIS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Angioid streaks and pseudoxanthoma elasticum
Authors: P. N. Schultz
Journal: JAMA (1991)

Angioid streaks are irregular, peripapillary brown to red curvilinear bands that extend in a weblike manner from the optic disc (Fig 1). Often confused with blood vessels, angioid streaks are wider, with tapering ends, lie below the normal retinal vasculature, and are readily discerned by direct ophthalmoscopy. Their importance lies in their association with a host of systemic disorders. Pseudoxanthoma elasticum (PXE), Paget's disease of the bone, and sickle-cell disease account for the majority of diseases linked to angioid streaks. PXE can be demonstrated in more than half the patients with angioid streaks<sup>1,2</sup>; in one large series, 85% of patients with PXE demonstrated angioid streaks.<sup>3</sup>Additional associated conditions include acromegaly, abetalipoproteinemia, diabetes mellitus, Ehlers-Danlos syndrome, hemochromatosis, facial hemochromatosis, hemolytic anemia, hypercalcinosis, hyperphosphatemia, neurofibromatosis, senile elastosis, Sturge-Weber syndrome, tuberous sclerosis, lead poisoning, and myopia.<sup>1</sup> Additional ocular findings in PXE include a diffuse, yellowish mottling of the retinal pigment
Incidence of secondary malignancies (SM) in patients (pts) with germ cell tumors (GCT) who received high-dose chemotherapy (HDCT): A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) database.
Authors: Simona Secondino, Andrea Necchi, Giovanni Rosti, Manuela Badoglio, Daniele Raggi, Patrizia Giannatempo, Francesco Lanza, Paolo Pedrazzoli
Journal: Journal of Clinical Oncology (2017)

4549 Background: Little is still known about the incidence of SM in young adult pts with GCT after HDCT, owing to the rarity of the disease, and the need for registries with long term follow-up (FUP) data. In Europe, the EBMT may provide a suitable platform for such retrospective analyses. Methods: Criteria for patient selection included diagnosis of GCT, adult male gender, ≥2yr of FUP after the administration of HDCT. Summary statistics were used to describe pt characteristics and outcomes. χ 2 tests were used to compare groups according to the length of FUP. Kaplan-Meier estimates were used to estimate overall survival (OS). Univariable Cox regression analyses examined clinical factors potentially associated with OS. Survival times were calculated from the HDCT administration date. To estimate the probability of developing SM, the cumulative incidence of SM was calculated for all pts. Results: From 1981 to 2014, 9,153 autografts, accounting for 5,100 pts, have been registered. Of them, 1,855 had ≥2yr of FUP. Among the latter, a total of 56 cases of SM were identified (3.0%). 28 (50%) had solid SM, 22 (39.3%) hematologic (hem) SM (5 had uncoded SM). Median age at first HDCT was 34 years (IQR: 30-42), median age at development of SM was 42 (37-51). 26 pts (46.4%) received single HDCT cycle, 22 (39.3%) multiple HDCT cycles (8 unknown). 31 pts had ≥5 yr FUP, 25 pts 2-5 yr FUP. The median latency of SM was 3.3yrs (IQR: 1.8-6.1) for hem SM and 5.6yrs (IQR: 1.2-10.8) for solid SM. Median FUP was 6.4yrs. Univariably, the type of SM (solid vs. hem) was significantly associated with OS. Hem vs solid SM: HR: 2.17 (95%CI: 1.19-4.97, p = 0.020). Median OS of pts who developed solid SM was 13.3yrs compared to 4.1yrs of those with hem SM. The retrospective nature of the data is the major limitation. Conclusions: In the largest European database of SM in GCT pts, we observed different trends for SM development according to the SM type. This information may be important for FUP guidelines of these pts. Dataset implementation is ongoing and we will compare the SM incidence from EBMT database with SM rates in the general EU population.
Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Farhad Ravandi, Sherry A. Pierce, Guillermo Garcia-Manero, Tapan M. Kadia, Elias J. Jabbour, Gautam Borthakur, Courtney D. DiNardo, Naval G. Daver, Nicholas J Short, Yesid Alvarado, Jorge E. Cortes, Christopher Kim, Michael A Kelsh, Aaron Jacob Katz, Richard Williams, Zhao Yang, Bhakti Mehta, Hagop M. Kantarjian
Journal: Blood (2018)
Pesticide Appliers, Biocides, and Birth Defects in Rural Minnesota
Authors: Vincent F. Garry, Dina Schreinemachers, Mary E. Harkins, Jack Griffith
Journal: Environmental Health Perspectives (1996)

Earlier studies by our group suggested the possibility that offspring of pesticide appliers might have increased risks of birth anomalies. To evaluate this hypothesis, 935 births to 34,772 state-licensed, private pesticide appliers in Minnesota occurring between 1989 and 1992 were linked to the Minnesota state birth registry containing 210,723 live births in this timeframe. The birth defect rate for all birth anomalies was significantly increased in children born to private appliers. Specific birth defect categories, circulatory/respiratory, urogenital, and musculoskeletal/integumental, showed significant increases. For the general population and for appliers, the birth anomaly rate differed by corp-growing region. Western Minnesota, a major wheat, sugar beet, and potato growing region, showed the highest rate of birth anomalies per/1000 live births: 30.0 for private appliers versus 26.9 for the general population of the same region. The lowest rates, 23.7/1000 for private appliers versus 18.3/1000 for the general population, occurred in noncorp regions. The highest frequency of use of chlorophenoxy herbicides and fungicides also occurred in western Minnesota. Births in the general population of western Minnesota showed a significant increase in birth anomalies in the same three birth anomaly categories as appliers and for central nervous system anomalies. This increase was most pronounced for infants conceived in the spring. The seasonal effect did not occur in other regions. The male/female sex ratio for the four birth anomaly categories of interest in areas of high phenoxy herbicide/fungicide use is 2.8 for appliers versus 1.5 for the general population of the same region (p = 0.05). In minimal use regions, this ratio is 2.1 for appliers versus 1.7 for the general population. The pattern of excess frequency of birth anomalies by pesticide use, season, and alteration of sex ratio suggests exposure-related effects in appliers and the general population of the crop-growing region of western Minnesota.
The Uniform Anatomical Gift Act
Authors: Alfred M. Sadler
Journal: JAMA (1968)

Few events in recent legal history have as great a potential for beneficial impact on the medical community as the final approval of the Uniform Anatomical Gift Act on July 30, 1968, at the most recent National Conference of the Commissioners on Uniform State Laws. The Uniform Act, which is appended, received the endorsement of the American Bar Association on Aug 7, 1968. The Act is designed to facilitate the donation and use of human tissues and organs for transplantation and other medical purposes and provides a favorable legal environment for such activities. The National Conference of Commissioners on Uniform State Laws is composed of law professors, lawyers, and judges, representing every state, whose function is to help make state laws more uniform and up to date. The Uniform Anatomical Gift Act is the product of three years of intensive study by a special committee of the conference and is particularly
Overview of Phthalate Ester Pharmacokinetics in Mammalian Species
Authors: William M. Kluwe
Journal: Environmental Health Perspectives (1982)

Phthalic acid esters, or phthalate esters, are generally well absorbed from the gastrointestinal tract following oral administration. Hydrolysis to the corresponding monoester metabolite, with release of an alcoholic substituent, largely occurs prior to intestinal absorption of the longer-chain alkyl derivatives such as di(2-ethylhexyl) phthalate (DEHP). Phthalate esters are widely distributed in the body, with the liver being the major, initial repository organ. Clearance from the body is rapid and there is only a slight cumulative potential. Short-chain dialkyl phthalates, such as dimethyl phthalate, can be excreted in an unchanged form or following complete hydrolysis to phthalic acid. Longer-chain compounds such as DEHP, however, are converted principally to polar derivatives of the monoesters by oxidative metabolism prior to excretion. A marked species difference in DEHP metabolism exists: primates (man, monkey, some rodent species) glucuronidate DEHP at the carboxylate moiety following hydrolysis of a single ester linkage, whereas rats appear to be unable to glucuronidate the monoester metabolite and oxidize the residual alkyl chain instead to various ketone and carboxylate derivatives. The major route of phthalate ester elimination from the body is urinary excretion. Certain phthalate esters are excreted in the bile but undergo enterohepatic circulation. The relationships of phthalate ester pharmacokinetics to their toxicological actions are unknown at the present time, largely due to a lack of elucidated mechanisms of toxic action.
Kaposi sarcoma and plasma cell dyscrasia
Authors: I. P. Law
Journal: JAMA (1974)

A patient with Kaposi sarcoma also had plasma cell leukemia. Review of the literature showed three additional patients with multiple myeloma, and several with paraproteinemia and bone marrow plasmacytosis. All patients shared the same fulminant clinical course. Generalized lymphadenopathy, hepatosplenomegaly, and anemia were common findings in patients with paraproteinemia and bone marrow plasmacytosis, but were uncommon in patients with multiple myeloma. (<i>JAMA</i>229:1329-1331, 1974)
Availability of NCI Monograph #37
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Availability of NCI Monograph #37 Get access JNCI: Journal of the National Cancer Institute, Volume 56, Issue 3, March 1976, Page 691, https://doi.org/10.1093/jnci/56.3.691-c Published: 01 March 1976
Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma
Authors: Colleen T. Harrington, Elena Sotillo, Aude Robert, Katharina E. Hayer, Agata M. Bogusz, James Psathas, Duonan Yu, Deanne Taylor, Chi V. Dang, Peter Klein, Michael D. Hogarty, Birgit Geoerger, Wafik S. El-Deiry, Joëlle Wiels, Andrei Thomas-Tikhonenko
Journal: Leukemia (2019)

Therapeutic targeting of initiating oncogenes is the mainstay of precision medicine. Considerable efforts have been expended toward silencing MYC, which drives many human cancers including Burkitt lymphomas (BL). Yet, the effects of MYC silencing on standard-of-care therapies are poorly understood. Here we found that inhibition of MYC transcription renders B-lymphoblastoid cells refractory to chemotherapeutic agents. This suggested that in the context of chemotherapy, stabilization of Myc protein could be more beneficial than its inactivation. We tested this hypothesis by pharmacologically inhibiting glycogen synthase kinase 3β (GSK-3β), which normally targets Myc for proteasomal degradation. We discovered that chemorefractory BL cell lines responded better to doxorubicin and other anti-cancer drugs when Myc was transiently stabilized. In vivo, GSK3 inhibitors (GSK3i) enhanced doxorubicin-induced apoptosis in BL patient-derived xenografts (BL-PDX), as well as in murine MYC-driven lymphoma allografts. This enhancement was accompanied by and required deregulation of several key genes acting in the extrinsic, death-receptor-mediated apoptotic pathway. Consistent with this mechanism of action, GSK3i also facilitated lymphoma cell killing by a death ligand TRAIL and by a death receptor agonist mapatumumab. Thus, GSK3i synergizes with both standard chemotherapeutics and direct engagers of death receptors and could improve outcomes in patients with refractory lymphomas.